2751-84-0

Basic information

• Product Name: 1-Methyl-2-(4'-broMophenyl)benziMidazole
• Synonyms: 1-Methyl-2-(4'-broMophenyl)benziMidazole;2-(4-BroMophenyl)-1-Methyl-1H-benzo[d]iMidazole;2-(4-Bromo-phenyl)-1-methyl-1H-benzoimidazole
• CAS NO: 2751-84-0
• Molecular Formula: C₁₄H₁₁BrN₂
• Molecular Weight: 287.15454
• Mol File: 2751-84-0.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-Methyl-2-(4'-broMophenyl)benziMidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Methyl-2-(4'-broMophenyl)benziMidazole(2751-84-0)
• EPA Substance Registry System: 1-Methyl-2-(4'-broMophenyl)benziMidazole(2751-84-0)

Safety Data

• Hazardous Substances Data: 2751-84-0(Hazardous Substances Data)

Usage

Properties and Specific Content of 1-Methyl-2-(4'-bromophenyl)benzimidazole

A molecular formula representing the compound's composition, consisting of 15 carbon atoms, 12 hydrogen atoms, 1 bromine atom, and 3 nitrogen atoms.
2. Benzimidazole derivative
A chemical compound derived from benzimidazole, which is a core structure consisting of a benzene ring fused to a five-membered imidazole ring.
3. Methyl and bromine substituents
The presence of a methyl group (CH3) and a bromine atom (Br) as substituents on the benzimidazole core, affecting the compound's properties and reactivity.
4. Building block in pharmaceutical synthesis
The compound is commonly used as an intermediate in the synthesis of various pharmaceutical compounds, contributing to the development of new drugs.
5. Research and development applications
The compound is utilized in research and development efforts, potentially leading to the discovery of new therapeutic agents and treatments.
6. Antimicrobial and antifungal properties
The compound exhibits strong activity against microorganisms and fungi, making it a potential candidate for the development of new antimicrobial and antifungal drugs.
7. Treatment of diseases and conditions
The compound has shown promise in the treatment of various diseases and conditions, such as cancer and inflammation, due to its unique structure and properties.
8. Value in medicinal and scientific research
The compound's unique structure and properties make it a valuable tool for researchers in the fields of medicine and science, potentially leading to new discoveries and advancements.

Upstream product

• 873-75-6 4-bromobenzenemethanol 
• 4760-34-3 N-methyl-1,2-phenylenediamine 
• 1122-91-4 4-bromo-benzaldehyde 
• 623-00-7 4-bromobenzenecarbonitrile 
• 95-54-5 1,2-diamino-benzene 
• 2622-74-4 2-(4-bromophenyl)-1H-benzimidazole 
• 74-88-4 methyl iodide 
• 25148-68-9 N-methylbenzene-1,2-diamine dihydrochloride 
• 586-76-5 4-Bromobenzoic acid 
• 1632-83-3 1-Methylbenzimidazole 
• 589-87-7 1,4-bromoiodobenzene 
• 616-38-6 carbonic acid dimethyl ester 

Downstream Products

• 1072346-26-9 2,9-bis(4-(1-methyl-1H-benzo[d]imidazol-2-yl)phenyl)-4,7-diphenyl-1,10-phenanthroline 
• 1126528-29-7 (E)-1-methyl-2-[4-(2-phenylethenyl)phenyl]-1H-benzimidazole 
• 1126528-30-0 2-[4-(cyclohexylamino)phenyl]-1-methyl-1H-benzimidazole 
• 1038865-99-4 1-methyl-2-[4-(phenylethynyl)phenyl]-1H-benzimidazole 
• 2562-78-9 1-methyl-2-(1,1'-biphenyl-4-yl)benzimidazole 
• 1352574-72-1 methyl (2E)-3-[4-(1-methyl-1H-benzimidazol-2-yl)phenyl]acrylate 
• 1584749-11-0 1-methyl-2-[4-(1-methyl-5-p-tolyl-1H-imidazol-2-yl)phenyl]-1H-benzo[d]imidazole 
• 1584749-10-9 2-{4-[5-(4-methoxyphenyl)-1-methyl-1H-imidazol-2-yl]phenyl}-1-methyl-1H-benzo[d]imidazole 
• 1584749-12-1 4-{1-methyl-2-[4-(1-methyl-1H-benzo[d]imidazol-2-yl)phenyl]-1H-imidazol-5-yl}benzonitrile 

Relevant articles and documents

Benzimidazole derivatives as potent and isoform selective tumor-associated carbonic anhydrase IX/XII inhibitors

We describe the synthesis of a series of 2-arylbenzimidazole derivatives bearing sulfonamide functionality (4a–d, 7a–c and 10) as well as hydroxamic acid (15a–b), carboxylic acid (16a–b), carboxamide (17a–b) and boronic acid (22a–b and 26) functionalities, which act as human carbonic anhydrase (hCA, EC 4.2.1.1) inhibitors. The newly synthesized benzimidazole derivatives were evaluated against 4 physiologically relevant CA isoforms (hCA I, II, IX, and XII), and especially the sulfonamide-containing benzimidazoles demonstrated intriguing inhibitory activity against tumor associated CA IX and XII with KI values in the range of 5.2–29.3 nM and 9.9–41.7 nM, respectively. Notably, compound 4c was the most potent and selective CA IX (KI = 6.6 nM) and XII (KI = 9.9 nM) inhibitor with a significant selectivity ratio over cytosolic CA I and II isoforms in the range of 3.4–25.2. In addition, compounds having hydroxamic acid (15a-b) or carboxylic acid (16a-b) functionalities resulted in greater selectivity ratios for CA IX/XII over CAI/II in the range of 4.1–121.5 although with KI values in lower micromolar potency (KIs = 0.36–0.85 μM for CA IX/XII).

Synthesis and characterization of green-emitting phosphorescent Ir(III) complexes based on phenyl benzimidazole ligand

Several new Ir(III) complexes with 2-(4-bromophenyl)-1H-benzo[d]imidazole or 2-(4-bromophenyl)- 1-methyl-benzo[d]imidazole ligands as cylcometalated ligand and acetylacetonate or picolinate as the ancillary ligand were synthesized and their structures and

Synthesis of 1-methylbenzimidazoles from carbonitriles

The NaH-mediated N-methylbenzimidazole formation starting from carbonitriles and N-methyl-1,2-phenylenediamine is reported to be a procedure compatible with acid-labile acetal protective groups within the starting materials. Products were further converte